

Breakdown of 8 leading vaccine candidates in Phase 3 that have done substantial deals with countries worldwide

Vaccine Candidate	Distribution of doses b/w rich and poorer countries (by end 2021)	Approx. Price^[1]	Public money received^[2]	Commitment to open sharing/ patents^[3]
Pfizer/ BioNTech	Total under contract: 1.128 billion doses Rich countries:1.082 billion (96%) Poorer countries: 54 million (4%)	\$19.50 a dose in US, two dose regimen. Represents up to 80% profit margin.	Yes- \$546 million to BioNTech from EU and German govt. \$2 billion contract with US government.	BioNTech is the holder of the IP and neither BioNTech or Pfizer has made any commitment to sharing IP or joining the WHO C-TAP
Moderna	Total under contract: 777 million Rich countries: 100% Poorer countries: 0%	\$12 to \$32 a dose, two dose regimen. Considered to be 'pandemic price only'	Yes- \$2.48 billion from US government, if certain milestones are met.	Yes, but limited. Will not enforce patents during the pandemic and willing to license IP post pandemic. No commitment to open sharing or WHO C-TAP.
Astra Zeneca/ Oxford	Total under contract: 3.233 billion Rich countries: 982 million (30%) Poorer countries: 2.251 billion (70%)	\$3 a dose from the licensed Indian Serum Institute two dose regimen and no profit during pandemic. No profit to low to middle income countries in perpetuity.	Yes – over \$1.9 billion from US and UK governments, CEPI AND GAVI.	IP owned by Oxford University, Exclusive License with AZ. AZ CEO openly opposed to any public sharing of technology and IP. Tech transfer between AZ and other developing country manufacturers, but not transparent. No commitment to open sharing or joining WHO C-TAP
Novavax	Total under contract: 1.376 billion Rich countries: 376 million (27%) Poorer countries 1 billion (73%)	\$16 a dose ^[4]	\$1.6 billion in US government funding ^[5]	Potential Tech transfer between Novavax and Indian Serum company but not transparent. No commitment to open sharing of technology or IP or of joining WHO C-TAP.

[1] More info at https://assets.oxfamamerica.org/media/documents/A_Shot_at_Recovery.pdf

[2] More info at https://assets.oxfamamerica.org/media/documents/A_Shot_at_Recovery.pdf

[3] More info at https://assets.oxfamamerica.org/media/documents/A_Shot_at_Recovery.pdf

[4] https://www.business-standard.com/article/current-affairs/coronavirus-vaccine-moderna-pfizer-to-oxford-covaxin-vaccine-price-who-gets-it-first-other-faqs-on-covid-vaccine-120112000362_1.html

[5] <https://ir.novavax.com/news-releases/news-release-details/novavax-announces-16-billion-funding-operation-warp-speed#:~:text=Novavax%20has%20been%20awarded%20%241.6,as%20early%20as%20late%202020.>

Johnson and Johnson	Total under contract: 1.268 billion Rich countries: 768 million (61%) Poorer countries 500 million (39%)	\$10 a dose, 'non-profit'-one dose regimen	\$1.5 billion from US govt	No commitment to open sharing of technology or IP or of joining WHO C-TAP
Sanofi/GSK	Total under contract: 1.232 billion Rich countries: 1.032 billion doses (84%) Poorer countries: 200 million doses (16%)	\$10.50 a dose ^[6] 'no-profit' during pandemic.	\$2.1 billion from US govt ^[7]	Loose commitment to 'sharing their technology' but no firm position on sharing IP and technology, and no commitment to joining WHO C-TAP
Sinovac	Total under contract: 229 million Rich countries (0%) Developing countries (100%) ^[8]	\$13.50-\$30 per dose ^[9]	Sinovac 40% owned by Chinese Govt. Also has benefited from loans from Chinese govt ^[10] .	Sinovac have shared technology with Indonesian and Brazilian producers but no commitment to WHO C-TAP. Xi Jinping has committed that all Chinese vaccines will be a 'global public good' ^[11]
Sputnik^[12]	Total under contract: 587 million Rich countries (0.3%) Poorer countries (99.7%)	\$10 a dose ^[13]	Gamaleya institute that is developing the vaccine is publicly owned and operates under the Ministry of Health.	Yes some commitment to share technology according to news reports ^[14] .

^[6] <https://www.barrons.com/articles/glaxo-and-sanofi-will-sell-100-million-covid-19-vaccine-doses-to-the-u-s-51596193212>

^[7] <https://www.fiercepharma.com/pharma/sanofi-gsk-win-hefty-2-1b-operation-warp-speed-funding-for-covid-19-vaccine>

^[8] Data on supply deals for Sinovac does not include doses secured for China, only supply deals agreed with other nations.

^[9] <https://www.reuters.com/article/us-health-coronavirus-china-vaccine-idUSKBN2710UQ>

^[10] <https://www.fiercepharma.com/manufacturing/china-s-sinovac-will-tackle-covid-19-shot-new-facility-backed-by-chinese-government>

^[11] <https://news.cgtn.com/news/2020-05-19/Chinese-vaccines-will-be-made-global-public-good-says-Xi-QCpFSGIL2g/index.html>

^[12] Data on supply deals for Gamaleya/ Sputnik does not include doses secured for Russia, only supply deals with other nations.

^[13] <https://www.theguardian.com/world/2020/nov/24/russia-says-data-on-sputnik-covid-vaccine-shows-95-efficacy>

^[14] <https://www.theguardian.com/world/2020/nov/24/russia-says-data-on-sputnik-covid-vaccine-shows-95-efficacy>